Terms: = Breast cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA AND Treatment
68 results:
1. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of cancer.
Majumder A
Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
[TBL] [Abstract] [Full Text] [Related]
2. Single-Nucleus Transcriptome Profiling of Locally Advanced Cervical Squamous Cell cancer Identifies Neural-Like Progenitor Program Associated with the Efficacy of Radiotherapy.
Zhang L; Ma J; Zhou D; Zhou J; Hu B; Ma X; Tang J; Bai Y; Chen H; Jing Y
Adv Sci (Weinh); 2023 Sep; 10(25):e2300348. PubMed ID: 37424047
[TBL] [Abstract] [Full Text] [Related]
3. Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis.
Hyung J; Lee JY; Kim JE; Yoon S; Yoo C; Hong YS; Jeong JH; Kim TW; Jeon S; Jun HR; Jung CK; Jang JP; Kim J; Chun SM; Ahn JH
ESMO Open; 2023 Jun; 8(3):101583. PubMed ID: 37327700
[TBL] [Abstract] [Full Text] [Related]
4. Drivers of racial, regional, and socioeconomic disparities in late-stage breast cancer mortality.
Moubadder L; Collin LJ; Nash R; Switchenko JM; Miller-Kleinhenz JM; Gogineni K; Ward KC; McCullough LE
Cancer; 2022 Sep; 128(18):3370-3382. PubMed ID: 35867419
[TBL] [Abstract] [Full Text] [Related]
5. RENORT: a project to analyze patterns of care in radiation oncology in Spain.
López-Torrecilla J; Palacios Eito A; Gómez-Caamaño A; Salinas Ramos J; Samper Ots P; Rodríguez Pérez A
Clin Transl Oncol; 2022 Jul; 24(7):1322-1332. PubMed ID: 35028930
[TBL] [Abstract] [Full Text] [Related]
6. ErbB4-mediated regulation of vasculogenic mimicry capability in breast cancer cells.
Kawahara R; Simizu S
Cancer Sci; 2022 Mar; 113(3):950-959. PubMed ID: 34971015
[TBL] [Abstract] [Full Text] [Related]
7. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
[TBL] [Abstract] [Full Text] [Related]
8. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract] [Full Text] [Related]
9. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
[TBL] [Abstract] [Full Text] [Related]
10. Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project.
López-Torrecilla J; González Sanchis D; Granero Cabañero D; García Miragall E; Almendros Blanco P; Hernandez Machancoses A; Brualla González L; Pastor Peidro J; Gordo Partearroyo JC; Rosello Ferrando J
Clin Transl Oncol; 2021 Aug; 23(8):1657-1665. PubMed ID: 33586123
[TBL] [Abstract] [Full Text] [Related]
11. The identification of highly upregulated genes in claudin-low breast cancer through an integrative bioinformatics approach.
Zayed H
Comput Biol Med; 2020 Dec; 127():103806. PubMed ID: 32788048
[TBL] [Abstract] [Full Text] [Related]
12. Synthetic NRG-1 functionalized DNA nanospindels towards HER2/neu targets for in vitro anti-cancer activity assessment against breast cancer MCF-7 cells.
Baig MMFA; Lai WF; Mikrani R; Jabeen M; Naveed M; Abbas M; Farooq MA; Ahsan A; Kassim SA; Khan GJ; Ansari MT
J Pharm Biomed Anal; 2020 Apr; 182():113133. PubMed ID: 32004770
[TBL] [Abstract] [Full Text] [Related]
13. Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic breast cancer, 2011 to 2014.
Yu JB; Pollack CE; Herrin J; Zhu W; Soulos PR; Xu X; Gross CP
Am J Clin Oncol; 2019 Jun; 42(6):493-499. PubMed ID: 31033511
[TBL] [Abstract] [Full Text] [Related]
14. Development of a Radiation Oncology-Specific Prospective Data Registry for Research and Quality Improvement: A Clinical Workflow-Based Solution.
Chen AM; Kupelian PA; Wang PC; Steinberg ML
JCO Clin Cancer Inform; 2018 Dec; 2():1-9. PubMed ID: 30652556
[TBL] [Abstract] [Full Text] [Related]
15. Mesenchymal stem cells drive paclitaxel resistance in ErbB2/ErbB3-coexpressing breast cancer cells via paracrine of neuregulin 1.
Chen J; Ren Q; Cai Y; Lin T; Zuo W; Wang J; Lin R; Zhu L; Wang P; Dong H; Zhao H; Huang L; Fu Y; Yang S; Tan J; Lan X; Wang S
Biochem Biophys Res Commun; 2018 Jun; 501(1):212-219. PubMed ID: 29715459
[TBL] [Abstract] [Full Text] [Related]
16. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
17. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ breast cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract] [Full Text] [Related]
18. nrg1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
[TBL] [Abstract] [Full Text] [Related]
19. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
[TBL] [Abstract] [Full Text] [Related]
20. Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Cardelli P; Scarpa S
Int J Biol Markers; 2017 Jul; 32(3):e333-e336. PubMed ID: 28430337
[TBL] [Abstract] [Full Text] [Related]
[Next]
